The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Hyper-O-GlcNAcylation Is Anti-apoptotic and Maintains Constitutive NF-κB Activity in Pancreatic Cancer Cells
Open accessAbstract
Cancer cell metabolic reprogramming includes a shift in energy production from oxidative phosphorylation to less efficient glycolysis even in the presence of oxygen (Warburg effect) and use of glutamine for increased biosynthetic needs. This necessitates greatly increased glucose and glutamine uptake, both of which enter the hexosamine biosynthetic pathway (HBP). The HBP end product UDP- N -acetylglucosamine (UDP-GlcNAc) is used in enzymatic post-translational modification of many cytosolic and nuclear proteins by O -linked β- N -acetylglucosamine ( O -GlcNAc). Here, we observed increased HBP flux and hyper- O -GlcNAcylation in human pancreatic ductal adenocarcinoma (PDAC). PDAC hyper- O -GlcNAcylation was associated with elevation of OGT and reduction of the enzyme that removes O -GlcNAc (OGA). Reducing hyper -O -GlcNAcylation had no effect on non-transformed pancreatic epithelial cell growth, but inhibited PDAC cell proliferation, anchorage-independent growth, orthotopic tumor growth, and triggered apoptosis. PDAC is supported by oncogenic NF-κB transcriptional activity. The NF-κB p65 subunit and upstream kinases IKKα/IKKβ were O -GlcNAcylated in PDAC. Reducing hyper- O -GlcNAcylation decreased PDAC cell p65 activating phosphorylation (S536), nuclear translocation, NF-κB transcriptional activity, and target gene expression. Conversely, mimicking PDAC hyper- O -GlcNAcylation through pharmacological inhibition of OGA suppressed suspension culture-induced apoptosis and increased IKKα and p65 O -GlcNAcylation, accompanied by activation of NF-κB signaling. Finally, reducing p65 O -GlcNAcylation specifically by mutating two p65 O -GlcNAc sites (T322A and T352A) attenuated the induction of PDAC cell anchorage-independent growth. Our data indicate that hyper- O -GlcNAcylation is anti-apoptotic and contributes to NF-κB oncogenic activation in PDAC. Background: Cancer cells rely on energy metabolism that requires increased glucose uptake and constitutive NF-κB activity for survival. Results: Pancreatic cancer cells display elevated O -GlcNAcylation, reduction of which inhibits cell survival and oncogenic NF-κB signaling. Conclusion: Hyper- O -GlcNAcylation is anti-apoptotic and contributes to NF-κB activation in pancreatic cancer. Significance: Targeting hyper- O -GlcNAcylation may serve as a novel therapeutic intervention in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207036 · Cited by 180
RetractedIto, H., Duxbury, M. S., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Surgery · doi:10.1016/j.surg.2004.05.032 · Cited by 84
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Hart, G. W., Slawson, C., Ramirez-Correa, G., & Lagerlof, O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060608-102511 · Cited by 1,317
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Varadhachary, G. R., Tamm, E. P., Abbruzzese, J. L., Xiong, H. Q., Crane, C. H., Wang, H., Lee, J. E., Pisters, P. W. T., Evans, D. B., & Wolff, R. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.011 · Cited by 876
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690 · cited 1×
“Cancer cells also consume glutamine at high rates and require high glutamine concentrations to survive (glutamine addiction) (4, 5).”
BackgroundPersistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., & Chiao, P. J. (1999) · PubMed · Cited by 651
p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637
Caldwell, S. A., Jackson, S. R., Shahriari, K. S., Lynch, T. P., Sethi, G., Walker, S., Vosseller, K., & Reginato, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.41 · Cited by 396
Self-citationO-GlcNAcase Uses Substrate-assisted Catalysis
Macauley, M. S., Whitworth, G. E., Debowski, A. W., Chin, D., & Vocadlo, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413819200 · Cited by 377
Self-citationFurukawa, T., Duguid, W. P., Rosenberg, L., Viallet, J., Galloway, D. A., & Tsao, M. (1996) · Europe PMC (PubMed Central) · Cited by 348
Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells
Gloster, T. M., Zandberg, W. F., Heinonen, J. E., Shen, D. L., Deng, L., & Vocadlo, D. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.520 · Cited by 335
Self-citationCharacterization of a Mouse Monoclonal Antibody Specific for O-Linked N-Acetylglucosamine
Comer, F. I., Vosseller, K., Wells, L., Accavitti, M. A., & Hart, G. W. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5132 · Cited by 295
Self-citationLynch, T. P., Ferrer, C. M., Jackson, S. R., Shahriari, K. S., Vosseller, K., & Reginato, M. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302547 · Cited by 286
Self-citationNFκB activation is associated with its O -GlcNAcylation state under hyperglycemic conditions
Yang, W. H., Park, S. Y., Nam, H. W., Kim, D. H., Kang, J. G., Kang, E. S., Kim, Y. S., Lee, H. C., Kim, K. S., & Cho, J. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806198105 · Cited by 263
O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy
Mi, W., Gu, Y., Han, C., Liu, H., Fan, Q., Zhang, X., Cong, Q., & Yu, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.01.009 · Cited by 259
Is cancer a disease of abnormal cellular metabolism? New angles on an old idea
Deberardinis, R. J. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31818b0d9b · Cited by 219
A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance
Wells, L., Vosseller, K., & Hart, G. W. (2003) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180300017 · Cited by 217
Self-citationMaier, H. J., Schmidt-Straßburger, U., Huber, M. A., Wiedemann, E. M., Beug, H., & Wirth, T. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.003 · Cited by 215
Snail1 is stabilized by O‐GlcNAc modification in hyperglycaemic condition
Park, S. Y., Kim, H. S., Kim, N. H., Ji, S., Cha, S. Y., Kang, J. G., Ota, I., Shimada, K., Konishi, N., Nam, H. W., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.254 · Cited by 202
Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813210106 · Cited by 193
MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling
Ahmad, R., Raina, D., Trivedi, V., Ren, J., Rajabi, H., Kharbanda, S., & Kufe, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1661 · Cited by 174
James, L. R., Tang, D., Ingram, A., Ly, H., Thai, K., Cai, L., & Scholey, J. W. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1146 · Cited by 174
Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancer
Liptay, S., Weber, C. K., Ludwig, L., Wagner, M., Adler, G., & Schmid, R. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11081 · Cited by 172
Zhu, Q., Zhou, L., Yang, Z., Lai, M., Xie, H., Wu, L., Xing, C., Zhang, F., & Zheng, S. (2012) · Medical Oncology · doi:10.1007/s12032-011-9912-1 · Cited by 168
Wice, B. M., Trugnan, G., Pinto, M., Rousset, M., Chevalier, G., Dussaulx, E., Lacroix, B., & Zweibaum, A. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89705-8 · Cited by 166
Kaadige, M. R., Looper, R. E., Kamalanaadhan, S., & Ayer, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901221106 · Cited by 162
Schneiderhan, W., Scheler, M., Holzmann, K.-H., Marx, M., Gschwend, J. E., Bucholz, M., Gress, T. M., Seufferlein, T., Adler, G., & Oswald, F. (2009) · Gut · doi:10.1136/gut.2009.181412 · Cited by 161
Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia
Shi, Y., Tomic, J., Wen, F., Shaha, S., Bahlo, A., Harrison, R., Dennis, J. W., Williams, R., Gross, B. J., Walker, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.152 · Cited by 147
Effects of Diabetes and Hyperglycemia on the Hexosamine Synthesis Pathway in Rat Muscle and Liver
Robinson, K. A., Weinstein, M. L., Lindenmayer, G. E., & Buse, M. G. (1995) · Diabetes · doi:10.2337/diab.44.12.1438 · Cited by 137
Wilson, W., & Baldwin, A. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1061 · Cited by 112
Gene expression of O-GlcNAc cycling enzymes in human breast cancers
Krześlak, A., Forma, E., Bernaciak, M., Romanowicz, H., & Bryś, M. (2011) · Clinical and Experimental Medicine · doi:10.1007/s10238-011-0138-5 · Cited by 110
Kong, R., Sun, B., Jiang, H., Pan, S., Chen, H., Wang, S., Krissansen, G. W., & Sun, X. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.10.001 · Cited by 82
Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase
Wu, M., Arimura, G. K., & Yunis, A. A. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910220615 · Cited by 77
Ren, Q., Kari, C., Quadros, M. R. D., Burd, R., McCue, P. A., Dicker, A. P., & Rodeck, U. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4158 · Cited by 56
Maher, J. C., Savaraj, N., Priebe, W., Liu, H., & Lampidis, T. J. (2005) · Pancreas · doi:10.1097/01.mpa.0000153327.46945.26 · Cited by 48
Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy
Wolff, R. A. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318074e6c3 · Cited by 24
Fan, Y., Mao, R., Zhao, Y., Yu, Y., Sun, W., Song, P., Shi, Z., Zhang, D., Yvon, E. S., Zhang, H., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018994 · Cited by 17
Cited by
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
KRAS: feeding pancreatic cancer proliferation
Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 393
Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer
Akella, N. M., Ciraku, L., & Reginato, M. J. (2019) · BMC Biology · doi:10.1186/s12915-019-0671-3 · Cited by 373
Metadata
- Authors
- Ma, Z., Vocadlo, D. J., & Vosseller, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 288
- Issue
- 21
- Pages
- 15121-15130
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1989476631
- Cited by
- 253
- References
- 47
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.